Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Emtricitabine, Rilpivirine, Tenofovir Drug Combination

Known as: Combination, Emtricitabine-Rilpivirine-Tenofovir Drug, Emtricitabine, Rilpivirine, Tenofovir Drug Combination [Chemical/Ingredient], Drug Combination, Emtricitabine-Rilpivirine-Tenofovir 
A pharmaceutical preparation that contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate. It is used to treat HIV INFECTIONS.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Background Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2018
2018
Objectives To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2017
Review
2017
BackgroundAim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular… Expand
  • table 1
  • table 3
  • table 4
  • table 5
  • table 6
2015
2015
BACKGROUND Completion rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low. We investigated the… Expand
  • figure 1
  • figure 2
Review
2013
Review
2013
Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Review
2013
Review
2013
A recent addition to the anti-human immunodeficiency virus armamentarium of drugs is rilpivirine, which is a potent non… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2012
Highly Cited
2012
BACKGROUND Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2012
2012
Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency… Expand
  • table 1
  • table 2
  • table 3
Review
2012
Review
2012
The rilpivirine/tenofovir/emtricitabine fixed‐dose combination (RTE FDC) (Complera, Eviplera) is a potent convenient, well… Expand
2012
2012
Rilpivirine (RPV) is a new non‐nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non‐inferiority to efavirenz… Expand